您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Motolimod(VTX-2337)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Motolimod(VTX-2337)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Motolimod(VTX-2337)图片
CAS NO:926927-61-9
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)458.6
FormulaC28H34N4O2
CAS No.926927-61-9
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 55 mg/mL (119.9 mM)
Water: <1 mg/mL
Ethanol: 15 mg/mL (32.7 mM)
SMILES Code O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC
Synonyms VTX-2337; VTX 2337; VTX 378; VTX2337; VTX-378; VTX378
实验参考方法
In Vitro

In vitro activity: VTX-2337 (Motolimod) stimulates the production of both TNFα with EC50 of 140 nM and IL-12 with EC50 of 120 nM in PBMCs. In monocytes and mDCs, VTX-2337 selectively induces the production of TNFα and IL-12 via NF-κB activation. VTX-2337 also stimulates IFNγ production from NK cells, augments the lytic function of NK cells and enhances ADCC.


Kinase Assay: The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out.


Cell Assay: PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell–mediated cytotoxicity is assessed by Calcein AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells.

In VivoIn an ovarian cancer mouse model, TX-2337 enhances the effect of pegylated liposomal doxorubicin (PLD); In male cynomolgus monkeys, VTX-2337 induced IL-1β and IL-18 production.
Animal modelMouse model
Formulation & Dosage 1 or 10 mg/kg, s.c. injection
ReferencesClin Cancer Res. 2012 Jan 15;18(2):499-509; J Clin Oncol 31, 2013 (suppl; abstr 3077).